Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone for Early VAP Prevention in Brain Injury
NCT02265406Phase 3Completed
- Sponsor
- CHU de Poitiers
- Start
- Oct 2015
- Primary completion
- Jul 2020
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) comparing Ceftriaxone with Placebo (2 arms). Primary endpoint: Incidence of early Ventilation Acquired Pneumonia at Day 7. Started Oct 2015; status: completed.
02
Drugs
ceftriaxone
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT02265406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265406.